Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 non-inferiority study of GSK MMRV vaccine 208136 versus Priorix and Priorix + Varilrix
2011-005882-19Phase 3
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of measles + mumps + rubella + varicella virus vaccine live, measles, mumps and rubella vaccine (live) and varicella virus vaccine live in measles, mumps, rubella and 1 more (3 arms), sponsored by GSK. Primary endpoint: Seroconversion rates for measles, mumps, rubella and varicella after second dose.
02
Drugs
measles + mumps + rubella + varicella virus vaccine livemeasles, mumps and rubella vaccine (live)varicella virus vaccine live
03
Conditions
measlesmumpsrubellachickenpox
Beyond the preview
Go deeper on 2011-005882-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005882-19.